ReviewCurrent oncology (Toronto, Ont.)2016
Duration of trastuzumab in patients with HER2-positive metastatic breast cancer in prolonged remission.
R Haq et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
8 papers cite it
this paperpooled itcites it